I Zlobec

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. ncbi Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy
    I Zlobec
    Institute of Pathology, University Hospital of Basel, Schonbeinstrasse 40, Basel 4031, Switzerland
    Br J Cancer 98:450-6. 2008
  2. ncbi HER2 gene status in primary breast cancers and matched distant metastases
    Coya Tapia
    University Department of Pathology of Basel and Baselland, Institute for Pathology, Schonbeinstrasse 40, Basel, 4003, Switzerland
    Breast Cancer Res 9:R31. 2007
  3. ncbi Role of the VEGF ligand to receptor ratio in the progression of mismatch repair-proficient colorectal cancer
    Manuela Eppenberger
    Institute of Pathology, University Hospital of Basel, Basel, Switzerland
    BMC Cancer 10:93. 2010
  4. ncbi TIA-1 cytotoxic granule-associated RNA binding protein improves the prognostic performance of CD8 in mismatch repair-proficient colorectal cancer
    Inti Zlobec
    Institute for Pathology, University of Basel, Basel, Switzerland
    PLoS ONE 5:e14282. 2010
  5. ncbi Node-negative colorectal cancer at high risk of distant metastasis identified by combined analysis of lymph node status, vascular invasion, and Raf-1 kinase inhibitor protein expression
    Inti Zlobec
    Institute of Pathology, University Hospital of Basel, Basel, Switzerland
    Clin Cancer Res 14:143-8. 2008
  6. ncbi Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer
    Inti Zlobec
    Institute of Pathology, University Hospital of Basel, Basel, Switzerland
    Cancer 112:495-502. 2008
  7. ncbi Value of staining intensity in the interpretation of immunohistochemistry for tumor markers in colorectal cancer
    Inti Zlobec
    Institute of Pathology, University Hospital of Basel, Schonbeinstrasse 40, Basel 4031, Switzerland
    Virchows Arch 451:763-9. 2007
  8. ncbi Combined histomorphologic and immunohistochemical phenotype to predict the presence of vascular invasion in colon cancer
    Inti Zlobec
    Institute of Pathology, University Hospital of Basel, Basel, Switzerland
    Dis Colon Rectum 52:1114-21. 2009
  9. ncbi Two-marker protein profile predicts poor prognosis in patients with early rectal cancer
    I Zlobec
    Institute of Pathology, University Hospital of Basel, Basel, Switzerland
    Br J Cancer 99:1712-7. 2008
  10. ncbi Tumor border configuration added to TNM staging better stratifies stage II colorectal cancer patients into prognostic subgroups
    Inti Zlobec
    Institute for Pathology, University of Basel, Basel, Switzerland
    Cancer 115:4021-9. 2009

Collaborators

Detail Information

Publications54

  1. ncbi Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy
    I Zlobec
    Institute of Pathology, University Hospital of Basel, Schonbeinstrasse 40, Basel 4031, Switzerland
    Br J Cancer 98:450-6. 2008
    ....
  2. ncbi HER2 gene status in primary breast cancers and matched distant metastases
    Coya Tapia
    University Department of Pathology of Basel and Baselland, Institute for Pathology, Schonbeinstrasse 40, Basel, 4003, Switzerland
    Breast Cancer Res 9:R31. 2007
    ..Here, we compared HER2 status on cytological specimens of distant metastases with the result from the primary carcinomas, and explored the prevalence of and the reasons for discrepant results...
  3. ncbi Role of the VEGF ligand to receptor ratio in the progression of mismatch repair-proficient colorectal cancer
    Manuela Eppenberger
    Institute of Pathology, University Hospital of Basel, Basel, Switzerland
    BMC Cancer 10:93. 2010
    ..The aim of this study was to elucidate the role of the VEGF ligand/receptor ratios on tumour progression and metastasis in patients with mismatch repair-proficient colorectal cancer...
  4. ncbi TIA-1 cytotoxic granule-associated RNA binding protein improves the prognostic performance of CD8 in mismatch repair-proficient colorectal cancer
    Inti Zlobec
    Institute for Pathology, University of Basel, Basel, Switzerland
    PLoS ONE 5:e14282. 2010
    ..The identification of innate and adaptive immune cells, that can complement the established prognostic effect of CD8 in MMR-proficient colorectal cancers patients, representing 85% of all cases, has not been performed...
  5. ncbi Node-negative colorectal cancer at high risk of distant metastasis identified by combined analysis of lymph node status, vascular invasion, and Raf-1 kinase inhibitor protein expression
    Inti Zlobec
    Institute of Pathology, University Hospital of Basel, Basel, Switzerland
    Clin Cancer Res 14:143-8. 2008
    ....
  6. ncbi Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer
    Inti Zlobec
    Institute of Pathology, University Hospital of Basel, Basel, Switzerland
    Cancer 112:495-502. 2008
    ..The objective of this study was to define a multimarker prognostic model of 5-year survival in patients with lymph node-negative, mismatch repair (MMR)-proficient colorectal cancer (CRC)...
  7. ncbi Value of staining intensity in the interpretation of immunohistochemistry for tumor markers in colorectal cancer
    Inti Zlobec
    Institute of Pathology, University Hospital of Basel, Schonbeinstrasse 40, Basel 4031, Switzerland
    Virchows Arch 451:763-9. 2007
    ....
  8. ncbi Combined histomorphologic and immunohistochemical phenotype to predict the presence of vascular invasion in colon cancer
    Inti Zlobec
    Institute of Pathology, University Hospital of Basel, Basel, Switzerland
    Dis Colon Rectum 52:1114-21. 2009
    ..The aim of this study was to develop a predictive model of vascular invasion in a large cohort of colon cancers with use of tumor-related features and immunohistochemical analysis of protein markers...
  9. ncbi Two-marker protein profile predicts poor prognosis in patients with early rectal cancer
    I Zlobec
    Institute of Pathology, University Hospital of Basel, Basel, Switzerland
    Br J Cancer 99:1712-7. 2008
    ..009) only. RHAMM and CD8(+) TILs may assist in identifying early stage rectal cancer patients facing a particularly poor prognosis and who may derive a benefit from preoperative therapy...
  10. ncbi Tumor border configuration added to TNM staging better stratifies stage II colorectal cancer patients into prognostic subgroups
    Inti Zlobec
    Institute for Pathology, University of Basel, Basel, Switzerland
    Cancer 115:4021-9. 2009
    ..The aim of this study was to determine the additive effect of tumor border configuration and peritumoral lymphocytic infiltration on the selection of patients for adjuvant therapy classified by TNM...
  11. ncbi Systematic assessment of the prognostic impact of membranous CD44v6 protein expression in colorectal cancer
    Inti Zlobec
    Institute of Pathology, University Hospital of Basel, Basel, Switzerland
    Histopathology 55:564-75. 2009
    ....
  12. ncbi Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients
    I Zlobec
    Institute for Pathology, University Hospital of Basel, 4031 Basel, Switzerland
    Br J Cancer 102:151-61. 2010
    ....
  13. ncbi Invasive front of colorectal cancer: Dynamic interface of pro-/anti-tumor factors
    Inti Zlobec
    Institute for Pathology, University Hospital Basel, , CH 4031 Basel, Switzerland
    World J Gastroenterol 15:5898-906. 2009
    ....
  14. ncbi Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer
    Inti Zlobec
    Institute for Pathology, University of Basel, Basel, Switzerland
    Int J Cancer 127:2569-75. 2010
    ..Specific KRAS mutation is an informative prognostic factor in both sporadic and hereditary CRC and applied in an algorithm with BRAF(V600E) and MSI may identify sporadic CRC patients with poor clinical outcome...
  15. ncbi Role of tumor size in the pre-operative management of rectal cancer patients
    Inti Zlobec
    Institute of Pathology, University Hospital of Basel, Basel, Switzerland
    BMC Gastroenterol 10:61. 2010
    ..The aim of this study was to determine the sensitivity, specificity and accuracy of tumor size for predicting T and N stages in pre-operatively untreated rectal cancers...
  16. ncbi Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients
    Inti Zlobec
    Institute for Pathology, University Hospital Basel, Basel, Switzerland
    World J Gastroenterol 16:4823-31. 2010
    ....
  17. ncbi Role of RHAMM within the hierarchy of well-established prognostic factors in colorectal cancer
    I Zlobec
    Institute of Pathology, University Hospital of Basel, Schonbeinstrasse 40, Basel, CH 4031, Switzerland
    Gut 57:1413-9. 2008
    ....
  18. ncbi Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer
    A Lugli
    Institute of Pathology, University of Basel, Basel, Switzerland
    Br J Cancer 103:382-90. 2010
    ..The aim of this study was to elucidate the prognostic impact of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and aldehyde dehydrogenase-1 (ALDH1) in colorectal cancer...
  19. ncbi New time-dependent approach to analyse the prognostic significance of immunohistochemical biomarkers in colon cancer and diffuse large B-cell lymphoma
    H Adams
    Institute of Pathology, University Hospital of Basel, Basel, Switzerland
    J Clin Pathol 62:986-97. 2009
    ..Here, the clinical value of time-dependent ROC curve analysis for improving the identification of high-risk patients with colon cancers and diffuse large B-cell lymphomas (DLBCL) is explored...
  20. ncbi Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis
    Inti Zlobec
    Institute for Pathology, University Hospital of Basel, Basel, Switzerland
    Int J Cancer 127:367-80. 2010
    ..These results indicate that molecular analysis for BRAF may be a useful biomarker for identifying patients with right-sided colon cancer with poor outcome who may benefit from a more individualized course of therapy...
  21. ncbi p16 expression in oropharyngeal cancer: its impact on staging and prognosis compared with the conventional clinical staging parameters
    C A Fischer
    Department of Otolaryngology Head and Neck Surgery, University Hospital, Petersgraben 4, Basel, Switzerland
    Ann Oncol 21:1961-6. 2010
    ..Therefore, the aim of this study was to evaluate the prognostic influence of p16 expression in OPSCC and compare its relevance with the established prognostic markers cT and cN classification and the clinical stages I-IV...
  22. ncbi Prognostic and predictive factors in colorectal cancer
    I Zlobec
    Institute of Pathology, University Hospital of Basel, Basel, Switzerland
    Postgrad Med J 84:403-11. 2008
    ..Additionally, an approach to improve the prognostic value of immunohistochemical protein markers is proposed...
  23. ncbi Assessment of mean EGFR gene copy number is a highly reproducible method for evaluating FISH in histological and cytological cancer specimens
    Inti Zlobec
    Institute for Pathology, University of Basel, Schonbeinstrasse 40, Basel 4031, Switzerland
    Lung Cancer 68:192-7. 2010
    ..This quantitative scoring system may constitute an alternative to current methods of gene copy number assessment and will further help to optimize patient selection for targeted therapies...
  24. ncbi Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer
    Tobias Zellweger
    Division of Urology, St Clara Hospital, Basel, Switzerland
    Int J Cancer 124:2116-23. 2009
    ..Analysis of Ki67 LI in these biopsies may help to better identify patients with clinically insignificant prostate cancer...
  25. ncbi Prognostic and predictive factors in colorectal cancer
    I Zlobec
    Institute of Pathology, University Hospital of Basel, Basel, Switzerland
    J Clin Pathol 61:561-9. 2008
    ..Additionally, an approach to improve the prognostic value of immunohistochemical protein markers is proposed...
  26. ncbi CD8+ lymphocytes/ tumour-budding index: an independent prognostic factor representing a 'pro-/anti-tumour' approach to tumour host interaction in colorectal cancer
    A Lugli
    Institute of Pathology, University of Basel, Basel, Switzerland
    Br J Cancer 101:1382-92. 2009
    ....
  27. ncbi Prognostic immunophenotypic biomarker studies in diffuse large B cell lymphoma with special emphasis on rational determination of cut-off scores
    Alexandar Tzankov
    Institute of Pathology, University of Basel, Basel, Switzerland
    Leuk Lymphoma 51:199-212. 2010
    ....
  28. ncbi RHAMM, p21 combined phenotype identifies microsatellite instability-high colorectal cancers with a highly adverse prognosis
    Inti Zlobec
    Institute of Pathology, University Hospital of Basel, Basel, Switzerland
    Clin Cancer Res 14:3798-806. 2008
    ..The aim of this study was to identify prognostic subgroups of microsatellite instability-high (MSI-H) colorectal cancers by combined analysis of 10 well-established immunohistochemical tumor markers and 7 clinicopathologic features...
  29. ncbi Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality?
    Claude A Fischer
    Department of Otolaryngology, Head and Neck Surgery, University Hospital, Basel, Switzerland
    Int J Cancer 126:1256-62. 2010
    ..The improved prognosis of p16 positive OPSCC is found after RT as well as after surgery...
  30. ncbi Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status
    Alessandro Lugli
    1Institute of Pathology, University Hospital of Basel, Basel, Switzerland
    Mod Pathol 21:1403-12. 2008
    ..Although associated with lower tumor grade, CK20 overexpression is an independent adverse prognostic factor in mismatch repair-proficient colorectal cancer...
  31. ncbi Local recurrence in mismatch repair-proficient colon cancer predicted by an infiltrative tumor border and lack of CD8+ tumor-infiltrating lymphocytes
    Inti Zlobec
    Institute of Pathology, University Hospital of Basel, Basel, Switzerland
    Clin Cancer Res 14:3792-7. 2008
    ....
  32. ncbi Differential significance of tumour infiltrating lymphocytes in sporadic mismatch repair deficient versus proficient colorectal cancers: a potential role for dysregulation of the transforming growth factor-beta pathway
    Kristi Baker
    Department of Pathology, McGill University, Lyman Duff Medical Building, 3755 University Street, Room B22, Montreal, Que, Canada H3A 2B4, and Institute of Pathology, University Hospital of Basel, Switzerland
    Eur J Cancer 43:624-31. 2007
    ....
  33. ncbi Is immunohistochemical epidermal growth factor receptor expression overestimated as a prognostic factor in head-neck squamous cell carcinoma? A retrospective analysis based on a tissue microarray of 365 carcinomas
    Claude Fischer
    Department of Otolaryngology, Head and Neck Surgery, University Hospital, 4031 Basel, Switzerland
    Hum Pathol 39:1527-34. 2008
    ....
  34. ncbi Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology
    Spasenija Savic
    Institute for Pathology, University Hospital Basel, Schonbeinstrasse 40, 4031 Basel, Switzerland
    Chest 138:137-44. 2010
    ....
  35. ncbi Co-overexpression of p21 and Ki-67 in head and neck squamous cell carcinoma relative to a significantly poor prognosis
    Claude A Fischer
    Department of Otolaryngology, Head and Neck Surgery, University Hospital, Basel, Switzerland
    Head Neck 33:267-73. 2011
    ..Tumor cell death-related markers, such as p21 and Ki-67, may predict response to therapy and improve treatment choice. We evaluated and compared the effect of their coexpression between patients treated by surgery or radiotherapy...
  36. ncbi High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients
    Daniel M Frey
    Department of Surgery, University Hospital of Basel, Basel, Switzerland
    Int J Cancer 126:2635-43. 2010
    ..13). Therefore, high frequency of tumor-infiltrating FOXP3(+) T(reg) is associated with early T stage and independently predicts improved disease-specific survival in MMR-proficient CRC patients...
  37. ncbi Prognostic value of cell cycle and apoptosis regulatory proteins in mismatch repair-proficient colorectal cancer: a tissue microarray-based approach
    Luigi Tornillo
    Institute of Pathology, University Hospital, Basel, Switzerland
    Am J Clin Pathol 127:114-23. 2007
    ..In addition, multimarker phenotypes are useful to identify colorectal cancer subgroups with different prognoses...
  38. ncbi BOB.1, CD79a and cyclin E are the most appropriate markers to discriminate classical Hodgkin's lymphoma from primary mediastinal large B-cell lymphoma
    Sylvia Hoeller
    Department of Pathology, University of Basel, Basel, Switzerland
    Histopathology 56:217-28. 2010
    ....
  39. ncbi The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy
    Spasenija Savic
    Institute for Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
    Int J Cancer 124:2899-904. 2009
    ..FISH is most useful in the diagnostically less certain cytology categories but does not provide additional information in clearly malignant cytology...
  40. ncbi Expression of CD24, P-cadherin and S100A4 in tumors of the ampulla of Vater
    Daniel Baumhoer
    Institute of Pathology, University of Basel, Basel, Switzerland
    Mod Pathol 22:306-13. 2009
    ..CD24 and S100A4, furthermore, can assist in the differential diagnosis of dysplasia vs invasive carcinoma...
  41. ncbi Immunophenotyping and oncogene amplifications in tumors of the papilla of Vater
    Daniel Baumhoer
    Institute of Pathology, University of Basel, Schonbeinstrasse 40, 4003 Basel, Switzerland
    Virchows Arch 453:579-88. 2008
    ..Fluorescence in situ hybridization analyses of therapeutic target genes (c-myc, EGFR1, CCND1, HER2) found CCND1 to represent the most frequently amplified gene in our series (7.5%)...
  42. ncbi ABCG5-positivity in tumor buds is an indicator of poor prognosis in node-negative colorectal cancer patients
    Lsabel Hostettler
    Institute for Pathology, University Hospital of Basel, Schoenbeinstrasse 40, Basel CH 4031, Switzerland
    World J Gastroenterol 16:732-9. 2010
    ..To analyze the expression of 8 putative cancer stem cell (CSC) markers within colorectal cancer tumor buds and to determine their prognostic impact in patients with this disease...
  43. ncbi Napoleon Bonaparte's gastric cancer: a clinicopathologic approach to staging, pathogenesis, and etiology
    Alessandro Lugli
    Institute of Pathology, University Hospital of Basel, Switzerland
    Nat Clin Pract Gastroenterol Hepatol 4:52-7. 2007
    ..We aimed to determine the etiology and pathogenesis of Napoleon's illness by a comparison of historical information with current clinicopathologic knowledge...
  44. ncbi KIT, PDGFRalpha and EGFR analysis in nephroblastoma
    Sylvia C Wetli
    Institute for Pathology, Basel University Hospital, Schoenbeinstrasse 40, CH 4031 Basel, Switzerland
    Virchows Arch 452:637-50. 2008
    ..Therefore, it remains open if KIT, PDGFRalpha or EGFR tyrosine kinase inhibition constitute a therapeutic target in nephroblastoma in the absence of KIT, PDGFRalpha or EGFR mutations...
  45. ncbi VEGF as a predictive marker of rectal tumor response to preoperative radiotherapy
    Inti Zlobec
    Department of Pathology, McGill University, Montreal, Quebec, Canada
    Cancer 104:2517-21. 2005
    ..The aim of this study was to determine whether VEGF expression in preirradiation tumor biopsies is a useful predictive marker of tumor response in patients with rectal cancer undergoing preoperative radiotherapy...
  46. ncbi The predictive value of apoptosis protease-activating factor 1 in rectal tumors treated with preoperative, high-dose-rate brachytherapy
    Inti Zlobec
    Department of Pathology, McGill University, Montreal, Quebec, Canada
    Cancer 106:284-6. 2006
    ..The objective of this study was to assess the value of apoptosis protease-activating factor 1 (APAF-1) as a predictive marker of response in rectal tumors treated with preoperative, high-dose-rate endorectal brachytherapy...
  47. ncbi Scoring of p53, VEGF, Bcl-2 and APAF-1 immunohistochemistry and interobserver reliability in colorectal cancer
    Inti Zlobec
    Department of Pathology, McGill University, Montreal, QC, Canada
    Mod Pathol 19:1236-42. 2006
    ..In conclusion, p53 and VEGF protein expression assessed by immunohistochemistry in colorectal cancer and scored as a percentage of positive tumor cells may be a viable alternative scoring method...
  48. ncbi A predictive model of rectal tumor response to preoperative radiotherapy using classification and regression tree methods
    Inti Zlobec
    Department of Pathology, McGill University Health Centre, Montreal, Quebec, Canada
    Clin Cancer Res 11:5440-3. 2005
    ....
  49. ncbi Overexpression of the receptor for hyaluronic acid mediated motility is an independent adverse prognostic factor in colorectal cancer
    Alessandro Lugli
    Department of Pathology, McGill University, Duff Medical Building, Montreal, QC, Canada
    Mod Pathol 19:1302-9. 2006
    ..012) and with complete RHAMM expression in presumed HNPCC (P=0.03). Increasing and complete RHAMM expressions are independent adverse prognostic factors in MMR-proficient CRC and presumed Lynch syndrome...
  50. ncbi Prognostic significance of mammalian sterile20-like kinase 1 in colorectal cancer
    Parham Minoo
    Department of Pathology, McGill University, Montreal, QC, Canada
    Mod Pathol 20:331-8. 2007
    ..These results are suggestive of a tumor suppressor role for Mst1 in human colorectal cancer...
  51. ncbi Role of the mitogen-activated protein kinase and phosphoinositide 3-kinase/AKT pathways downstream molecules, phosphorylated extracellular signal-regulated kinase, and phosphorylated AKT in colorectal cancer-a tissue microarray-based approach
    Alessandro Lugli
    Department of Pathology, McGill University, Montreal, Canada H3A 2B4
    Hum Pathol 37:1022-31. 2006
    ....
  52. ncbi Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer
    Inti Zlobec
    Department of Pathology, McGill University, Montreal, Quebec, Canada
    J Clin Pathol 60:1112-6. 2007
    ..Cut-off scores for determining positivity of biomarkers detected by immunohistochemistry are often set arbitrarily and vary between reports...
  53. ncbi Loss of raf-1 kinase inhibitor protein expression is associated with tumor progression and metastasis in colorectal cancer
    Parham Minoo
    Department of Pathology, McGill University, Montreal, Canada
    Am J Clin Pathol 127:820-7. 2007
    ..Methylation analysis of 28 cases showed that loss of RKIP expression is unlikely to be due to promoter methylation.Loss of RKIP expression is a marker of tumor progression and distant metastasis in MMR-proficient and MMR-deficient CRCs...
  54. ncbi Loss of APAF-1 expression is associated with tumour progression and adverse prognosis in colorectal cancer
    Inti Zlobec
    Department of Pathology, McGill University, Duff Medical Building, 3775 University Street, Montreal, Canada H3A 2B4
    Eur J Cancer 43:1101-7. 2007
    ..001). No methylation was found in the selected region of APAF-1. APAF-1 is a marker of tumour progression in MMR-proficient CRC and an independent adverse prognostic factor in MLH1-negative CRC...